Denosumab (Prolia®)

Assessment Status NCPE Assessment Process Complete
Drug Denosumab
Brand Prolia®
Indication For the Prevention of Osteoporotic Fractures in Postmenopausal Women
Assessment Process
Rapid review commissioned 27/05/2010
Rapid review completed 01/07/2010
Rapid review outcome We consider denosumab a cost-effective therapy for the prevention of osteoporotic fractures in postmenopausal women in the Irish healthcare setting